目的观察复方苦参注射液联合注射用雷替曲塞和注射用奥沙利铂治疗晚期结肠癌的临床疗效。方法选择2014年1月—2015年6月襄阳市中心医院收治的晚期结肠癌患者78例作为研究对象,随机分为对照组和治疗组,每组各39例。对照组患者采用雷替曲...目的观察复方苦参注射液联合注射用雷替曲塞和注射用奥沙利铂治疗晚期结肠癌的临床疗效。方法选择2014年1月—2015年6月襄阳市中心医院收治的晚期结肠癌患者78例作为研究对象,随机分为对照组和治疗组,每组各39例。对照组患者采用雷替曲塞联合奥沙利铂化疗方案：注射用雷替曲塞3 mg/m2,溶于生理盐水注射液100 m L,第1天静脉滴注;注射用奥沙利铂85 mg/m2,溶于5%葡萄糖注射液500 m L,第1天静脉滴注。治疗组患者在对照组的基础上加用复方苦参注射液20 m L,溶于生理盐水注射液100 m L中,第1~7天静脉滴注。2周为一个周期,所有患者化疗2个周期。观察两组的临床近期疗效和不良反应。结果治疗后,对照组客观缓解率为38.5%,疾病控制率为71.8%;治疗组客观缓解率为46.2%,疾病控制率为87.2%;两组客观缓解率和疾病控制率比较差异具有统计学意义（P〈0.05）。治疗组的恶心呕吐、转氨酶升高、周围神经毒性和白细胞减少的发生率均显著低于对照组,组间比较差异具有统计学意义（P〈0.05）。结论复方苦参注射液联合注射用雷替曲塞和注射用奥沙利铂治疗晚期结肠癌能具有较好的临床近期疗效,不良反应减少,值得在临床上进一步推广和应用。展开更多
AIM: To evaluate the efficacy and safety of gemcitabine-oxaliplatin (GEMOX) combined with huachansu (cinobufagin) injection treatment in patients with locally advanced or metastatic gallbladder carcinoma (GBC), and to...AIM: To evaluate the efficacy and safety of gemcitabine-oxaliplatin (GEMOX) combined with huachansu (cinobufagin) injection treatment in patients with locally advanced or metastatic gallbladder carcinoma (GBC), and to assess the quality of life (QOL) of such patients. METHODS: Twenty-fi ve patients with locally advanced or metastatic GBC were treated with intravenous gemcitabine (1000 mg/m2) over 30 min on days 1 and 8, 2 h infusion of oxaliplatin (120 mg/m2) on day 1, and 2-3 h infusion of huachansu (20 mL/m2) on days -3-11, every 3-4 wk. Treatment was continued until occurrence of unacceptable toxicity or disease progression. QOL of patients was assessed by the EORTC QLQ-C30 at baseline, at the end of the fi rst, third and sixth chemotherapy cycles, and 1 mo after the treatment. RESULTS: Among the 25 patients with a median age of 64 years (range 42-78 years), 23 were evaluable in the study. A total of 137 cycles of therapy were performed and the median cycle was 5 (range 1-8) per patient. Out of the 23 patients whose response couldbe evaluated, 8 partial responses (PR) were observed (34.8%), while 7 patients (30.4%) demonstrated a stable disease (SD). The disease control rate was 65.2%. Progression of cancer was observed in 8 (34.8%) patients. The median progression-free and overall survival time was 5.8 mo (95% CI: 4.5-7.1 mo) and 10.5 mo, respectively. The therapy was well tolerated, with moderate myelosuppression as the main toxicity. Anemia grade 2 was seen in 16.0%, neutropenia grade 3 in 8.0% and thrombocytopenia grade 3 in 24.0% of patients, respectively. Non-hematologic toxicity ranged from mild to moderate. No death occurred due to toxicity. The QOL of patients was improved after chemotherapy, and the scores of QOL were increased by 10 to 20 points. CONCLUSION: GEMOX combined with huachansu (cinobufagin) injection is well tolerated, effective, thus improving the QOL of patients with advanced GBC.展开更多
目的讨论替吉奥联合奥沙利铂治疗晚期胃癌患者的临床疗效。方法选取2016年3—2017年3月青海大学附属医院收治的晚期胃癌患者80例,随机分为对照组和治疗组,每组各40例。对照组静脉滴注注射用奥沙利铂,90 mg/m^2溶于5%葡萄糖溶液500 m L,...目的讨论替吉奥联合奥沙利铂治疗晚期胃癌患者的临床疗效。方法选取2016年3—2017年3月青海大学附属医院收治的晚期胃癌患者80例,随机分为对照组和治疗组,每组各40例。对照组静脉滴注注射用奥沙利铂,90 mg/m^2溶于5%葡萄糖溶液500 m L,持续3~4 h,1次/14 d。治疗组在对照组的基础上口服替吉奥胶囊,2粒/次,2次/d。两组患者持续治疗28 d。观察两组患者临床疗效,比较治疗前后两组患者生存质量及血清肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)和IL-10水平。结果治疗后,对照组客观缓解率和疾病控制率分别为52.5%、72.5%,均分别显著低于治疗组的77.5%、92.5%,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组躯体功能、情绪功能、认知功能和社会功能评分显著高于对照组,食欲下降、便秘和睡眠障碍症状评分显著低于对照组,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗后两组上述评分均显著优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清TNF-α、IL-6、IL-10水平均显著低于治疗前,同组比较差异具有统计学意义(P<0.05);且治疗组患者上述血清因子水平显著低于对照组,两组比较差异具有统计学意义(P<0.05)。结论替吉奥联合奥沙利铂治疗晚期胃癌临床疗效较好,能改善患者的生存质量,有效降低患者血清TNF-α、IL-6、IL-10的表达,具有一定的临床应用价值。展开更多
目的探讨斑蝥酸钠维生素B6联合雷替曲塞和奥沙利铂治疗晚期结直肠癌的临床疗效。方法选取2013年4月—2016年4月在无锡市第二中医医院和盐城市第二人民医院接受治疗的晚期结直肠癌患者50例,按照治疗方法的差别分成对照组(25例)和治疗组(2...目的探讨斑蝥酸钠维生素B6联合雷替曲塞和奥沙利铂治疗晚期结直肠癌的临床疗效。方法选取2013年4月—2016年4月在无锡市第二中医医院和盐城市第二人民医院接受治疗的晚期结直肠癌患者50例,按照治疗方法的差别分成对照组(25例)和治疗组(25例)。对照组静脉滴注注射用雷替曲塞,3 mg/m2,第1天给药,1次/3周;同时静脉滴注注射用奥沙利铂,130 mg/m2,第1天给药,1次/3周。治疗组在对照组的基础上静脉滴注斑蝥酸钠维生素B6注射液,30 m L加入5%葡萄糖注射液250 m L,1次/d。两组患者均连续治疗6周。观察两组的临床疗效,比较两组患者生存质量、血清基质金属蛋白酶-9(MMP-9)和MMP-2水平及不良反应发生情况。结果治疗后,对照组和治疗组的客观缓解率(ORR)分别为16.00%、44.00%,临床获益率(CBR)分别为44.00%、72.00%,两组患者临床疗效比较差异有统计学意义(P<0.05)。治疗后,两组生存质量总改善率分别为64.00%、88.00%,且治疗组患者生存期较对照组显著延长,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者血清MMP-2、MMP-9水平均降低,同组治疗前后差异具有统计学意义(P<0.05);且与对照组相比,治疗组上述血清学指标的降低程度更显著,两组比较差异有统计学意义(P<0.05)。结论斑蝥酸钠维生素B6联合雷替曲塞和奥沙利铂治疗晚期结直肠癌具有很好的临床疗效,不仅能够使机体免疫力提高,还有助于改善患者生活质量,具有一定的临床推广应用价值。展开更多
文摘目的观察复方苦参注射液联合注射用雷替曲塞和注射用奥沙利铂治疗晚期结肠癌的临床疗效。方法选择2014年1月—2015年6月襄阳市中心医院收治的晚期结肠癌患者78例作为研究对象,随机分为对照组和治疗组,每组各39例。对照组患者采用雷替曲塞联合奥沙利铂化疗方案：注射用雷替曲塞3 mg/m2,溶于生理盐水注射液100 m L,第1天静脉滴注;注射用奥沙利铂85 mg/m2,溶于5%葡萄糖注射液500 m L,第1天静脉滴注。治疗组患者在对照组的基础上加用复方苦参注射液20 m L,溶于生理盐水注射液100 m L中,第1~7天静脉滴注。2周为一个周期,所有患者化疗2个周期。观察两组的临床近期疗效和不良反应。结果治疗后,对照组客观缓解率为38.5%,疾病控制率为71.8%;治疗组客观缓解率为46.2%,疾病控制率为87.2%;两组客观缓解率和疾病控制率比较差异具有统计学意义（P〈0.05）。治疗组的恶心呕吐、转氨酶升高、周围神经毒性和白细胞减少的发生率均显著低于对照组,组间比较差异具有统计学意义（P〈0.05）。结论复方苦参注射液联合注射用雷替曲塞和注射用奥沙利铂治疗晚期结肠癌能具有较好的临床近期疗效,不良反应减少,值得在临床上进一步推广和应用。
文摘AIM: To evaluate the efficacy and safety of gemcitabine-oxaliplatin (GEMOX) combined with huachansu (cinobufagin) injection treatment in patients with locally advanced or metastatic gallbladder carcinoma (GBC), and to assess the quality of life (QOL) of such patients. METHODS: Twenty-fi ve patients with locally advanced or metastatic GBC were treated with intravenous gemcitabine (1000 mg/m2) over 30 min on days 1 and 8, 2 h infusion of oxaliplatin (120 mg/m2) on day 1, and 2-3 h infusion of huachansu (20 mL/m2) on days -3-11, every 3-4 wk. Treatment was continued until occurrence of unacceptable toxicity or disease progression. QOL of patients was assessed by the EORTC QLQ-C30 at baseline, at the end of the fi rst, third and sixth chemotherapy cycles, and 1 mo after the treatment. RESULTS: Among the 25 patients with a median age of 64 years (range 42-78 years), 23 were evaluable in the study. A total of 137 cycles of therapy were performed and the median cycle was 5 (range 1-8) per patient. Out of the 23 patients whose response couldbe evaluated, 8 partial responses (PR) were observed (34.8%), while 7 patients (30.4%) demonstrated a stable disease (SD). The disease control rate was 65.2%. Progression of cancer was observed in 8 (34.8%) patients. The median progression-free and overall survival time was 5.8 mo (95% CI: 4.5-7.1 mo) and 10.5 mo, respectively. The therapy was well tolerated, with moderate myelosuppression as the main toxicity. Anemia grade 2 was seen in 16.0%, neutropenia grade 3 in 8.0% and thrombocytopenia grade 3 in 24.0% of patients, respectively. Non-hematologic toxicity ranged from mild to moderate. No death occurred due to toxicity. The QOL of patients was improved after chemotherapy, and the scores of QOL were increased by 10 to 20 points. CONCLUSION: GEMOX combined with huachansu (cinobufagin) injection is well tolerated, effective, thus improving the QOL of patients with advanced GBC.
文摘目的探讨斑蝥酸钠维生素B6联合雷替曲塞和奥沙利铂治疗晚期结直肠癌的临床疗效。方法选取2013年4月—2016年4月在无锡市第二中医医院和盐城市第二人民医院接受治疗的晚期结直肠癌患者50例,按照治疗方法的差别分成对照组(25例)和治疗组(25例)。对照组静脉滴注注射用雷替曲塞,3 mg/m2,第1天给药,1次/3周;同时静脉滴注注射用奥沙利铂,130 mg/m2,第1天给药,1次/3周。治疗组在对照组的基础上静脉滴注斑蝥酸钠维生素B6注射液,30 m L加入5%葡萄糖注射液250 m L,1次/d。两组患者均连续治疗6周。观察两组的临床疗效,比较两组患者生存质量、血清基质金属蛋白酶-9(MMP-9)和MMP-2水平及不良反应发生情况。结果治疗后,对照组和治疗组的客观缓解率(ORR)分别为16.00%、44.00%,临床获益率(CBR)分别为44.00%、72.00%,两组患者临床疗效比较差异有统计学意义(P<0.05)。治疗后,两组生存质量总改善率分别为64.00%、88.00%,且治疗组患者生存期较对照组显著延长,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者血清MMP-2、MMP-9水平均降低,同组治疗前后差异具有统计学意义(P<0.05);且与对照组相比,治疗组上述血清学指标的降低程度更显著,两组比较差异有统计学意义(P<0.05)。结论斑蝥酸钠维生素B6联合雷替曲塞和奥沙利铂治疗晚期结直肠癌具有很好的临床疗效,不仅能够使机体免疫力提高,还有助于改善患者生活质量,具有一定的临床推广应用价值。
